ClinicalTrials.gg
WithdrawnNCT07428369LINKER-MM8Updated Jun 18, 2026

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

A Phase 2/3 interventional study of Linvoseltamab and Bortezomib in Multiple Myeloma (MM), sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Why this study was withdrawn
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.

Enrollment
16th of 16
0 · median 168
Started
2026
with 6 others
Phase 2/3
Only one
of the 16
Registered
15th of 16
by date
Lead sponsor
10 of 16
Regeneron Pharmaceuticals

Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 16th largest by enrollment, is one of 7 that started in 2026, is the only one in phase 2/3, and was the 15th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About linvoseltamab

linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing linvoseltamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).

This study is evaluating a drug called linvoseltamab in combination with standard therapies for multiple myeloma called bortezomib (V) and lenalidomide (R). This combination is abbreviated as Linvo-VR.

The aim of this study is to compare how well Linvo-VR, with and without ASCT, treats myeloma to how well the current standard of care regimen for NDMM treats myeloma. That current standard of care regimen includes the drugs daratumumab (D), bortezomib (V), lenalidomide (R), and dexamethasone (d). This combination is referred to as DVRd. The study is also evaluating if Linvo-VR treats myeloma well enough that ASCT is no longer needed with the first myeloma treatments.

The study is looking at several other research questions, including:

  • What side effects may happen from taking linvoseltamab
  • How much linvoseltamab is in the blood at different times
  • Whether the body makes antibodies against the linvoseltamab (which could make the drug less effective or could lead to side effects)
03

Conditions studied

  • Multiple Myeloma (MM)

Browse trials for

Keywords

  • Autologous Stem Cell Transplantation (ASCT)
  • Transplant-Eligible
  • Linvoseltamab
  • Newly Diagnosed Multiple Myeloma (NDMM)
  • High-dose chemotherapy
  • Bortezomib (V)
  • Lenalidomide (R)
  • Daratumumab (D), bortezomib (V), lenalidomide (R), dexamethasone (d) (DVRd)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants must have a or cytologically confirmed diagnosis of multiple myeloma, which requires the presence of clonal bone marrow plasma cells ≥10% or -proven bony or extramedullary plasmacytoma, and at least one other criteria as defined by the SLiM (>=60%, Light chains I/U >10, Magnetic resonance imaging >1 focal lesion) CRAB (Calcium elevation, Renal insufficiency, Anemia, Bone disease) criteria
  2. Participants must have , as defined in the protocol
  3. Participants must be considered eligible for high-dose chemotherapy (melphalan) and per local standard guidelines
  4. (ECOG) performance status ≤2
  5. Must be willing to defer ASCT

Key Exclusion Criteria:

  1. Any prior therapy for Monoclonal Gammopathy of Undetermined Significance (MGUS), Monoclonal Gammopathy of Renal Significance (MGRS), Smoldering Multiple Myeloma (SMM), or MM, with the exception of those defined in the protocol
  2. Participants who have received or are receiving any agent or cell therapy with known or suspected activity against MM (or another plasma cell disorder), or those whose AEs due to agents administered earlier (such as radiation and/or ) have not recovered to a severity of grade 0 or grade 1
  3. Participants with non-secretory MM, diagnosis of plasma cell leukemia (>20% circulating plasma cells), symptomatic amyloidosis (including myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes).
  4. Participants who have known Central Nervous System (CNS) or meningeal involvement with MM or known or suspected Progressive Multifocal Leukoencephalopathy (PML), a history of a neurocognitive condition or CNS movement disorder, OR a history of seizure, (TIA), or stroke within 12 months prior to study randomization
  5. Another besides MM that is progressive or has required treatment in the 3 years preceding randomization with the exceptions defined in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Linvo-VR with ASCT

    Drug: Linvoseltamab · Drug: Bortezomib · Drug: Lenalidomide

  • Experimental
    Linvo-VR without ASCT

    Drug: Linvoseltamab · Drug: Bortezomib · Drug: Lenalidomide

  • Active comparator
    DVRd with ASCT

    Drug: Bortezomib · Drug: Lenalidomide · Drug: Daratumumab · Drug: Dexamethasone

Interventions

  • Administered per the protocol

    Also known as: REGN5458, Lynozyfic™

  • Administered per the protocol

    Also known as: Velcade®

  • Administered per the protocol

    Also known as: Revlimid®

  • Administered per the protocol

    Also known as: Darzalex Faspro®,, Darzalex®

  • Administered per the protocol

    Also known as: Dexahexal®,, Decadron®

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Phase 2

    Time frame: Up to day 112

  2. Severity of TEAEs

    Phase 2

    Time frame: Up to day 112

  3. Achievement of Complete Response or better (≥CR) per International Myeloma Working Group (IMWG) criteria

    Phase 2

    Time frame: Up to day 112

  4. Minimal Residual Disease (MRD) negative CR at 10^-5 per IMWG criteria

    Phase 3

    Time frame: Up to 12 months

  5. Progression Free Survival (PFS) per IMWG

    Phase 3

    Time frame: Up to 5 years

Secondary outcomes

  1. Occurrence of TEAEs

    Phase 2

    Time frame: Up to 3.5 years

  2. Severity of TEAEs

    Phase 2

    Time frame: Up to 3.5 years

  3. Occurrence of Serious Adverse Events (SAEs)

    Phase 2

    Time frame: Up to 3.5 years

  4. Severity of SAEs

    Phase 2

    Time frame: Up to 3.5 years

  5. Occurrence of Cytokine Release Syndrome (CRS)

    Phase 2

    Time frame: Up to day 30

  6. Severity of CRS

    Phase 2

    Time frame: Up to day 30

  7. Occurrence of Cell-Associated Neurotoxicity Syndrome (ICANS)

    Phase 2

    Time frame: Up to day 30

  8. Severity of ICANS

    Phase 2

    Time frame: Up to day 30

  9. Achievement of objective response [Partial Response or better (≥PR)] per IMWG criteria

    Time frame: Up to 5 years

  10. Time to ≥PR per IMWG criteria

    Time frame: Up to 5 years

  11. Time to Very Good Partial Response or better (≥VGPR) per IMWG criteria

    Time frame: Up to 5 years

  12. Time to ≥CR per IMWG criteria

    Time frame: Up to 5 years

  13. Achievement of MRD negative (at 10^-5 sensitivity) CR per IMWG criteria

    Time frame: Up to 5 years

  14. Duration Of Response (DOR) of ≥PR per IMWG criteria

    Time frame: Up to 5 years

  15. Duration of ≥VGPR per IMWG criteria

    Time frame: Up to 5 years

  16. Duration of ≥CR per IMWG criteria

    Time frame: Up to 5 years

  17. PFS per IMWG criteria

    Time frame: Up to 5 years

  18. Second PFS (PFS2) per IMWG criteria

    Time frame: Up to 5 years

  19. Overall Survival (OS)

    Time frame: Up to 5 years

  20. Concentrations of total linvoseltamab in serum

    Time frame: Up to 5 years

  21. Occurrence of TEAEs

    Phase 3

    Time frame: Up to 5 years

  22. Severity of TEAEs

    Phase 3

    Time frame: Up to 5 years

  23. Occurrence of SAEs

    Phase 3

    Time frame: Up to 5 years

  24. Severity of SAEs

    Phase 3

    Time frame: Up to 5 years

  25. Occurrence of second primary malignancies

    Phase 3

    Time frame: Up to 5 years

  26. Change from baseline in Global Health Status (GHS) per European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30)

    Phase 3 The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported Quality of Life (QoL). For GHS, scores range from 1 = "very poor" to 5 = "excellent" with higher scores indicating better functioning and positive changes from baseline indicate improvement.

    Time frame: Up to 5 years

  27. Change from baseline in physical functioning per EORTC QLQ-C30

    Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Physical functioning is scored from 1 'very poor' to 5 'excellent,' with higher scores indicating better functioning; positive changes from baseline indicate improvement.

    Time frame: Up to 5 years

  28. Change from baseline in role functioning per EORTC QLQ-C30

    Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Role functioning is scored from 1 'very poor' to 5 'excellent,' with higher scores indicating better functioning; positive changes from baseline indicate improvement.

    Time frame: Up to 5 years

  29. Change from baseline in pain per EORTC QLQ-C30

    Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Pain is scored from 1 = "not at all" to 9 = "very much". Higher scores indicate higher symptom burden.

    Time frame: Up to 5 years

  30. Change from baseline in fatigue per EORTC QLQ-C30

    Phase 3 The EORTC QLQ-C30 is a validated 30-item questionnaire designed to measure patient-reported quality of life. Fatigue is scored from1 = "not at all" to 9 = "very much". Higher scores indicate higher symptom burden.

    Time frame: Up to 5 years

  31. Change from baseline in disease symptoms per EORTC QLQ- Multiple Myeloma Module 20 (MY20)

    Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 6 items for disease symptoms. A high score for a symptom scale/item represents a high level of symptomatic problem.

    Time frame: Up to 5 years

  32. Change from baseline in treatment side effects per EORTC QLQ-MY20

    Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 10 items for treatment side effects. A high score for a symptom scale/item represents a high level of symptomatic problem.

    Time frame: Up to 5 years

  33. Change from baseline in body image per EORTC QLQ-MY20

    Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 1 item for treatment body image. A high score for a symptom scale/item represents a high level of symptomatic problem.

    Time frame: Up to 5 years

  34. Change from baseline in future perspective per EORTC QLQ-MY20

    Phase 3 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire includes 3 items for treatment future perspective. A high score for a symptom scale/item represents a high level of symptomatic problem.

    Time frame: Up to 5 years

  35. Change from baseline in EuroQoL-5 Dimensions 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS)

    Phase 3 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".

    Time frame: Up to 5 years

  36. Time to definitive deterioration in GHS per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  37. Time to definitive deterioration in physical functioning per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  38. Time to definitive deterioration in role functioning per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  39. Time to definitive deterioration in pain per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  40. Time to definitive deterioration in fatigue per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  41. Time to definitive deterioration in disease symptoms per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  42. Time to definitive deterioration in treatment side effects per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  43. Time to definitive deterioration in body image per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  44. Time to definitive deterioration in future perspective per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  45. Time to definitive deterioration in EQ-5D-5L VAS

    Phase 3

    Time frame: Up to 5 years

  46. Time to first improvement in GHS per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  47. Time to first improvement in physical functioning per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  48. Time to first improvement in role functioning per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  49. Time to first improvement in pain per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  50. Time to first improvement in fatigue per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  51. Time to first improvement in disease symptoms per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  52. Time to first improvement in treatment side effects per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  53. Time to first improvement in body image per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  54. Time to first improvement in future perspective per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  55. Time to first improvement in EQ-5D-5L VAS

    Phase 3

    Time frame: Up to 5 years

  56. Proportion with clinically meaningful improvement in GHS per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  57. Proportion with clinically meaningful improvement in physical functioning per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  58. Proportion with clinically meaningful improvement in role functioning per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  59. Proportion with clinically meaningful improvement in pain per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  60. Proportion with clinically meaningful improvement in fatigue per EORTC QLQ-C30

    Phase 3

    Time frame: Up to 5 years

  61. Proportion with clinically meaningful improvement in disease symptoms per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  62. Proportion with clinically meaningful improvement in treatment side effects per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  63. Proportion with clinically meaningful improvement in body image per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  64. Proportion with clinically meaningful improvement in future perspective per EORTC QLQ-MY20

    Phase 3

    Time frame: Up to 5 years

  65. Proportion of clinically meaningful improvement in EQ-5D-5L VAS

    Phase 3

    Time frame: Up to 5 years

  66. Mean proportion of time with high side effect bother as measured by Functional Assessment of Cancer Therapy (FACIT)- Item Global Population 5 (GP5)

    Phase 3 FACIT-Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much).

    Time frame: Up to 5 years

  67. Proportion of patients with high side effect bother as measured by FACIT- Item GP5

    Phase 3

    Time frame: Up to 5 years

  68. Occurrence of Anti-Drug Antibody (ADA) to linvoseltamab in serum

    Phase 3

    Time frame: Up to 5 years

  69. Magnitude of ADA to linvoseltamab in serum

    Phase 3

    Time frame: Up to 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for May 2038, 143 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 23, 2026
StartEst.
Jun 5, 2026
Primary completionEst.
May 21, 2038
CompletionEst.
May 21, 2038
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07428369
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Jun 5, 2026 (estimated)
Primary completion
May 21, 2038 (estimated)
Completion
May 21, 2038 (estimated)
Last update
Jun 18, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion